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Proteomic approaches have proven powerful at identifying large numbers of proteins, but there are fewer reports of functional
characterization of proteins in biological tissues. Here, we describe an experimental approach that fractionates proteins released
fromhumanplatelets,linkingbioassayactivitytoidentity.Weusedconsecutiveorthogonalseparationplatformstoensuresensitive
detection: (a) ion-exchange of intact proteins, (b) SDS-PAGE separation of ion-exchange fractions and (c) HPLC separation of
tryptic digests coupled to electrospray tandem mass spectrometry. Migration of THP-1 monocytes in response to complete or
fractionated platelet releasate was assessed and located to just one of the forty-nine ion-exchange fractions. Over 300 proteins
were identiﬁed in the releasate, with a wide range of annotated biophysical and biochemical properties, in particular platelet
activation, adhesion, and wound healing. The presence of PEDF and involucrin, two proteins not previously reported in platelet
releasate, was conﬁrmed by western blotting. Proteins identiﬁed within the fraction with monocyte promigratory activity and not
in other inactive fractions included vimentin, PEDF, and TIMP-1. We conclude that this analytical platform is eﬀective for the
characterization of complex bioactive samples.
1.Introduction
Platelets are anucleate cells that are important for haemosta-
sis, thrombosis, and atherosclerotic disease. A number of
bleeding disorders arise as a result of mutations in the genes
for proteins involved in platelet aggregation. Thus, altered
or deregulated platelet function underpins many diseases,
and platelet proteins are potential targets for novel thera-
peutic agents. Previous proteomic studies of intact platelets
have collectively identiﬁed hundreds of proteins using a
variety of fractionation strategies including 2-dimensional
electrophoresis (2DE), multidimensional chromatographic
separations, membrane prefractionation techniques, and
adsorption to combinatorial hexapeptide ligand libraries
[1–6]. Following activation by agonists such as thrombin,
platelets release storage granules and membrane vesicles that
contain prothrombotic (e.g., ﬁbrinogen), mitogenic (e.g.,
platelet derived growth factor), immunomodulatory (e.g.,
neutrophil-activating peptide 2), and adhesive (e.g., platelet
endothelial cell adhesion molecule) proteins. A previous
study from our laboratory using a MuDPIT (multidimen-
sional protein identiﬁcation technology) approach identiﬁed
over 300 proteins secreted by platelets upon thrombin
activation [1]. These proteins may modulate the interaction
of platelets with their local cellular environment. Indeed,
platelet releasate has previously been shown to induce
endothelial cell permeability, endothelial cell chemotaxis,
and corneal epithelial cell proliferation in cellular assays [7–
9].
The issue of abundant (often housekeeping) proteins
masking regulatory proteins of lower abundance (such as
signaling proteins and cytokines) continues to be a challeng-
ing issue for proteomics particularly in the case of bioﬂuids.
Plasma has a signiﬁcant dynamic range, with more than
10 orders of magnitude separating albumin concentration
and the rarest measurable proteins identiﬁed to date [10].
Protein and peptide chromatography prior to MS analysis
can partly address this issue. The classical example of this2 Journal of Biomedicine and Biotechnology
is MuDPIT, ﬁrst described by Andrew Link and colleagues
[11]. In the ﬁrst dimension, ion-exchange chromatography
(IEC) separates peptides based on ionic interactions with the
solid phase and an increasing salt buﬀe r .T h i si sc o u p l e dt o
RP-HPLC to create a second dimension of separation prior
to MS analysis. Complex biological samples have also been
successfully separated in multiple dimensions at the protein
level. For instance, a number of studies have used 1D SDS-
PAGE to separate proteins by molecular weight prior to MS
analysis [12–15].
While modern proteomics experiments permit the anal-
ysis of hundreds to thousands of proteins in complex
samples, the most powerful use of this data would combine
information on protein activity with the identities of the
active proteins. The emerging ﬁeld of chemical proteomics
[16] addresses this question elegantly for an increasing num-
ber of enzymatic functions through formation of covalent
enzyme-substrate conjugates [17]. However, many higher-
level cellular functions encompassing multiple steps are not
amenable to these approaches. A limited number of studies
involving proteomic fractionation combined with biological
assay and subsequent MS identiﬁcation of active proteins
have been reported [18–20]. Here we use IEC to separate
the platelet releasate for subsequent assay of monocyte
migratory activity. IEC relies on electrostatic interactions
between the proteins and the chromatography matrix, so
that fractionation primarily depends on net protein charge.
We chose a scheme, incorporating both cation and anion
resins, in preference to a size-based fractionation scheme
because many secreted proteins are small (<20KDa) and so
would cofractionate. We further separated the IEC fractions
by SDS-PAGE, carrying out multiple (∼30) LCMS runs per
IEC fraction, thus ensuring extensive coverage of the platelet
releasate proteome. By correlating the presence of proteins
in active fractions (and conversely by discounting the con-
tribution of proteins detected in inactive fractions), a more
focused list of active proteins could be obtained compared to
those obtained from conventional proteomics approaches.
2. Methods
2.1. Preparation of Platelet Releasate. Plasma and washed
platelet samples were prepared from 100mL of blood
drawn from healthy human volunteers free from analgesic
medication for 10 days using a modiﬁcation of the method
described by Mendelsohn [21]. Following centrifugation of
blood for 10 minutes at 150g, platelet-rich plasma (PRP)
was harvested. Platelets were pelleted by centrifugation at
720g for 10 minutes and subsequently resuspended in
a modiﬁed HEPES buﬀer (JNL buﬀer) (130mM NaCl,
10mM trisodium citrate, 9mM NaHCO3, 6mM dextrose,
0.9mM MgCl2,0 . 8 1 m MK H 2PO4,1 0 m MT r i sp H7 . 4 )
at a concentration of 2 × 109 platelets/mL or 2 × 108
platelets/mL.
Platelet suspensions were supplemented with 1.8mM
CaCl2, incubated at 37
◦Ci na na g g r e g o m e t e ru n d e rc o n -
stant stirring conditions (1100rev/min), and stimulated
with 5μM thrombin receptor-activating peptide (TRAP)
for 3 minutes. Platelet releasate was isolated as previously
described [1]. Brieﬂy, platelets were removed from the
releasatebytwosequentialcentrifugalspinsat750g,protease
inhibitor cocktail (Merck Biosciences, UK) was added, and
releasate samples were stored at −20
◦C.
2.2. Ion-Exchange Chromatography. Platelet releasate sam-
ples (from 2 × 109 platelets/mL preparations) were desalted
using Zeba spin columns (Pierce, Rockford, Illinois) as per
manufacturerinstructionspriortoion-exchangechromatog-
raphy (IEC) fractionation. Subsequently, 0.75mL of desalted
platelet releasate was injected onto ProPac anion and cation-
exchange columns (Dionex, UK) conﬁgured in series on the
Ultimate TM 3000 LC system (Dionex, UK). The ﬂow rate
was set at 200μL/min and fractions were collected every
minute into a 96-well plate. A UV detector (wavelength
of 280nm) was used to identify eluting peptides. After an
initial 10-minutes equilibration, a gradient of 0.02M–0.5M
salt was delivered to the columns by appropriate mixing of
IEC buﬀer A (20mM K2HPO4 pH 9.0) and IEC buﬀer B
(20mM K2HPO4 pH 9.0, 1M NaCl) over a time course of
25-minutes. This was followed by a 5-minute wash with IEC
buﬀer B (“clean oﬀ”) and 5-minute equilibration with IEC
buﬀer A.
2.3. Cell Culture and Migration Assay. Am o n o c y t i cl e u -
kaemiacellline,THP-1,wasobtainedfromEACC(Salisbury,
UK). Cells were grown in RPMI 1640 medium, supple-
mented with 10% FBS, 2mM/L L-glutamine, 100U/mL
penicillin, and 100μg/mL streptomycin. The cells were
passaged every 5–7 days. All cells were maintained as a sus-
pension culture at 37
◦Ci n5 %C O 2/95% ambient air. THP-
1 migration was measured using a Boyden chamber assay.
THP-1 cells were centrifuged at 1000g and resuspended
in serum-free media (SFM) at a concentration of 1 × 106
cells/mL. Of this cell suspension, 100μL was added to the
upper chamber of an 8μm pore-size transwell (Corning BV,
Schiphol-Rijk, The Netherlands). For the purpose of the
migration assay, 2μL of three successive IEC fractions (from
1–49) were pooled and added to the lower chamber. SFM
was added to a ﬁnal volume of 1mL. A positive control of
10% FBS in SFM was used. The transwell inserts were placed
into the lower chamber and incubated for 2 hours at 37
◦Ci n
5% CO2/95% ambient air. The number of two populations
of cells migrating to the bottom chamber was assessed,
the cells migrating to the bottom chamber and adhering
to the membrane and the cells migrating to the bottom
chamber without adhering to the membrane. Nonmigrating
cells on the upper surface of the membrane were removed by
gentle scraping with a cotton bud and adherent migratory
cells on the lower surface of the membrane were counted
following ﬁxation with 2.5% glutaraldehyde for 20 minutes
and staining for 1 hour with crystal violet stain. The number
of cells migrating and adhering to the underside of the
membrane was evaluated by counting ten random non
overlapping 40X ﬁelds. To assess the number of cells which
migrated through the membrane but did not adhere to the
membrane, the media in the lower chamber was collected
and centrifuged at 1000g. The cell pellet was resuspendedJournal of Biomedicine and Biotechnology 3
in 16μL PBS, 4μL trypan blue was added, and the cells were
counted using a hemocytometer.
2.4. Visualisation of Fractionated Proteins. Protein from IEC
fractions was methanol/chloroform precipitated [22]a n d
separated using 4%–20% acrylamide gradient gels (Pierce,
Rockford, Illinois) [23]. Protein gels were silver stained using
a SilverSnap kit (Pierce, Rockford, Illinois).
2.5. LC-MS/MS (Liquid Chromatography-Tandem Mass Spec-
trometry). SDS-PAGE gel lanes were cut into 32 bands and
digested in-gel with sequencing grade trypsin (Promega,
Ireland) according to the method of Shevchenko et al.
[15]. The resulting peptide mixtures were resuspended in
0.1% formic acid and analysed by nanoelectrospray liquid
chromatography mass spectrometry (Nano-LC MS/MS). An
HPLC instrument (Dionex, UK) was interfaced with an
LTQ ion trap mass spectrometer (ThermoFinnigan, CA).
Chromatography buﬀer solutions (“Buﬀer A”, 5% acetoni-
trile and 0.1% formic acid; “Buﬀer B”, 80% acetonitrile
and 0.1% formic acid) were used to deliver a 60-minute
gradient (35 minutes to 45% Buﬀer B, 10 minutes to
90%, hold for 10 minutes, 3 minutes to 5%, hold for 15
minutes).Aﬂowrateof2μL/minwasusedattheelectrospray
source. Spectra were searched using the SEQUEST algo-
rithm against the International Protein Index (IPI) database
(http://www.ebi.ac.uk/IPI/IPIhelp.html), as described pre-
viously [24]. The probability-based evaluation program,
Protein Prophet, was used for ﬁltering identiﬁcations [25].
2.6. Bioinformatic Analysis. Ontological analysis of protein
identiﬁcations was performed using the GOTM website
(http://babelomics2.bioinfo.cipf.es/)[ 26]. A hypergeometric
test corrected for multiple testing (Bonferroni) was used to
determine statistically signiﬁcant enrichments (P<. 01).
To analyse the range of proteins identiﬁed in this study,
the predicted molecular weight and isoelectric point of each
protein were obtained using the Compute pL/MW tool from
the ExPASy server (http://expasy.org/).
2.7. Western Blot. Western blot was carried out as previously
described [27] with the following modiﬁcations. Equal
volumes of resting and TRAP-stimulated platelet releasates
were loaded into each well and separated on a 4%–20%
acrylamide gradient gel. The primary antibody for the
detection of PEDF was a rabbit polyclonal antibody (1 in
1000 dilution overnight at 4◦C) from Upstate Cell Signaling
Solutions (Buckingham, UK). The primary antibody for the
detection of involucrin was a mouse monoclonal antibody
(1 in 200 dilution overnight at 4◦C) from Sigma (Dublin,
Ireland). Anti-mouse and anti-rabbit secondary horseradish
peroxidase(HRP)conjugatedantibodies wereobtained from
Cell Signaling Technology (Danvers, MA). Peroxidase activ-
ity was detected using luminol chemiluminescent substrate
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
3. Results
3.1. Strategy for Linking Biological Activities to Individual
Tissue Fractions. The overall strategy is shown in Figure 1.
We used ion-exchange chromatography (IEC) to separate
a complex protein mixture, proteins secreted by human
platelets in response to the agonist thrombin receptor-
activating peptide (TRAP), into fractions suitable for both
biological analysis and identiﬁcation by mass spectrometry.
While strategies such as MuDPIT separate at the level of the
trypticpeptide;separationattheproteinlevelreducessample
complexity and facilitates correlation of the presence (or
absence) of a protein with an observed biological function.
TheeﬀectofplateletreleasateonTHP-1monocytemigration
was investigated to test this strategy. Addition of serum to
media in the bottom of the Boyden chamber indeed stim-
ulated migration of monocytes (data not shown), although
interestingly serum stimulation did not cause the cells to
adhere to the underside of the Boyden chamber membrane
(Figure 2(a)). In contrast, both MCP-1 (a well-known pro-
migratory chemokine for monocytes) and platelet releasate
induced monocyte migration simultaneously caused these
suspended cells to adhere to the underside of the membrane
(Figure 2(a)). The eﬀect of releasate was dose dependent
(Figure 2(b)).
To identify releasate fractions with biological activity,
consecutive IEC fractions were initially pooled in groups
of three for the analysis of THP-1 migration. One pooled
fraction, 25–27, was found to strongly induce mono-
cyte migration (Figure 2(c)). We repeated the assay using
the individual fractions 25, 26, and 27. In this second
experiment, the pro-migratory activity could be localized
to fraction 27 (Figure 2(d)). Data displayed in Figure 2
describes “adherent migration”, that is, cells which migrated
through the 8μm pores and adhered to the underside of the
membrane. In order to identify the proteins present in each
fraction, each lane from the SDS-PAGE gels of fractionated
platelet releasate (Figure 3(a)) was divided into 32 bands,
digested with trypsin, and subjected to LC-MS/MS, and the
corresponding proteins were identiﬁed by database search
(Supplementary Table 1 in supplementary material available
online at doi: 10.1155/2010/107859). For each fraction,
spectral counts (counts of tandem mass spectrometry events
leadingtoproductiveproteinidentiﬁcation),anapproximate
indicatorofproteinabundance,werecalculated,andthetotal
spectral count for all proteins in the fractions was deter-
mined (Supplementary Table 2). The top ﬁfty proteins by
spectral counts are displayed in Table 1. The spectral counts
(Figure 3(b))andnumberofproteinsidentiﬁed(Figure 3(c))
correlate with each other, and also with the staining patterns
of the proteins on the gels (Figure 3(a)). Of the 315 proteins
identiﬁed, 220 were found in a unique fractions (70%),
suggesting eﬀective IEC separation (Figure 3(d)). Abundant
proteins were often found in adjacent fractions, for example,
thrombospondin was most abundant in Fraction 26 but
also identiﬁed in Fractions 27 and 28. Some proteins
were identiﬁed in nonadjacent fractions, perhaps reﬂecting
diﬀerential migration of protein isoforms (e.g., splicing,
proteolytic cleavage, and posttranslational modiﬁcation).
3.2. Biological and Biophysical Properties of Fractionated
Platelet Releasate. Our analysis resulted in the high con-
ﬁdence identiﬁcation of 315 proteins and represents an4 Journal of Biomedicine and Biotechnology
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Figure 1: Strategy for linking function and protein identity in bioﬂuids. An oﬀ-line MuDPIT strategy was used to identify biologically active
proteins from a complex mixture. Proteins released from platelets were separated by SCX/SAX chromatography. The collected fractions were
analyzed for pro-migratory activity using a monocyte Boyden chamber assay. The fractions were separated in the second dimension by SDS-
PAGE, and gel lanes were excised and the proteins were digested with trypsin. The resulting peptides were separated by RP-HPLC, ionized
by electrospray, and subjected to MS/MS to identify potential pro-migratory proteins.
extensive proteomic coverage of platelet releasate. The iden-
tiﬁed proteins demonstrated an extensive array of annotated
biophysical properties as are evidenced by the wide range
of PI and molecular weights predicted for the identiﬁca-
tions (Figure 4(b)), suggesting that the method introduced
no strong bias against any category of protein. Similarly,
proteins with a wide range of annotated activities were
identiﬁed. The frequency of diﬀerent functional annota-
tions within the released platelet proteins was compared
to the expected frequency based on all human proteins
annotated in the Gene Ontology (GO) database using the
GOTM program [26]. Hemostasis, blood coagulation, and
wound healing were identiﬁed as being overrepresented
biological processes, as well as molecular functions such as
actin binding, protein binding, and calcium ion binding
(P< .01) (Figure 4(a)). GO levels between 2 and 5 were used
to avoid overgeneral and overspeciﬁc functions. Many of
these enriched functions appear to be relevant to potential
endocrine platelet functions, for instance, “hemostasis”,
“wound healing”, and “coagulation”, while others may be rel-
evanttotheplateletactivationresponse(“plateletactivation”,
“localization”, “purine nucleotide binding”, and “calcium
binding”).
3.3.InvestigationofActiveFraction. Thirty-twoproteinswere
found in Fraction 27, the only fraction that stimulated
monocyte migration (Table 2). Of these proteins, six were
not found in any other fraction in our study. These proteins
included tissue inhibitor of metalloproteinase 1 (TIMP-1),
vimentin, and pigment epithelium-derived growth factor
(PEDF).Spectralcounts,functions,andinformationontheir
identiﬁcation in other fractions are listed for all fraction 27
proteins in Table 2. The bold areas highlight those proteins
that are only found in Fraction 27. The identiﬁed proteins
were compared to datasets from previous studies of platelet
proteins to determine whether the identiﬁed proteins had
been previously identiﬁed in platelets [1, 2, 5, 6, 27–31].
The presence of two novel platelet proteins, PEDF and
involucrin (see Supplementary Table 1 for full details),
was conﬁrmed by immunoblotting (Figure 5). PEDF was
identiﬁed at the expected mass of approximately 50kDa
in platelet releasate preparations with additional heavierJournal of Biomedicine and Biotechnology 5
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Figure 2: A pro-migratory eﬀect identiﬁed in unfractionated and fractionated platelet releasate. THP-1 monocyte cell migration was
measured using a Boyden chamber assay over 2 hours. (a) Assessment of migrated cells adhering to the underside of the membrane in
response to platelet releasate, Serum (10%), and MCP-1 (100ng/mL). N = 3; (b) Adherent migrated THP-1 cells in response to 10, 25 or
100μL platelet releasate; N = 3. (c) Fractions were pooled in groups of three and added to serum-free media (SFM) in the bottom chamber.
Positive controls include MCP-1 and unfractionated platelet releasate; N = 3. (d) Localisation of the pro-migratory eﬀect of Fractions 25–27
to an individual fraction. Each fraction (2μL) was added to serum-free media in the bottom chamber of a separate well and compared with
the combination of Fractions 25–27 (2μL of each fraction). TRAP = thrombin receptor-activating peptide. N = 3. The average number of
migrated cells adhering to the underside of the membrane was calculated from ten 40X ﬁelds of view.
bands also detected (Figure 5(a)). Previous studies have
identiﬁed PEDF at 50kDa with additional bands at 66kDa
and 76kDa in Y79 cell lysates using this antibody. PEDF
was found to a greater extent in TRAP-stimulated platelet
releasate compared to resting/unstimulated releasate. The
highest band (76kDa) was also present in the resting
releasate from four diﬀerent individual donors. Involucrin
was identiﬁed in TRAP-stimulated platelet releasates at a
mass of approximately 120kDa (Figure 5(b)).
4. Discussion
One aim of proteomics is to address biological questions
through the identiﬁcation and characterization of proteins
en mass. In this study, we developed an approach to separate
a complex biological mixture using orthogonal separation
methods. At the protein level, we used IEC followed by
SDS-PAGE, while at the peptide level, reverse phase chro-
matography preceded MS analysis. We successfully applied6 Journal of Biomedicine and Biotechnology
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Figure 3: Fractionation of the platelet releasate by ion-exchange chromatography. (a) From each releasate fraction collected, 80μLw a s
precipitated to remove salt, resuspended in 10μL of Laemmli buﬀer, and separated by MW on 4%–20% acrylamide gels. Silver-stained
gels are displayed below corresponding sections of the ion-exchange UV detected chromatogram. A UV wavelength of 280nm was used to
detect eluting peptides. (b) The number of spectra detected in each fraction following LC MS/MS of tryptically digested 1D gel pieces. (c)
The number of proteins identiﬁed in each fraction using SEQUEST with a score greater than 0.9. (d) Representation of the number and
proportion of proteins in a single fraction, two adjacent fractions; two nonadjacent fractions, or more than two fractions.Journal of Biomedicine and Biotechnology 7
GO biological process Molecular function
GO
level observed expected P-value GO
level observed expected P-value
4 regulation of body ﬂuids 14 1.88 5.01647E−09 3 protein binding 100 82.04 .008838235
5 hemostasis 13 1.68 1.12792E−08 3 nucleotide binding 52 33.63 .000751555
4 blood coagulation 12 1.57 4.88352E−08 4 purine nucleotide binding 48 28.78 .000228825
4 coagulation 12 1.61 6.33109E−08 5 adenyl nucleotide binding 39 23.35 .000946115
5 wound healing 12 1.75 1.67416−07 5 calcium ion binding 34 14.89 5.28281E−06
4 physiological response to
wounding 19 5.88 6.93829E−06 4 cytoskeletal protein binding 21 5.88 4.74782E−07
4 response to wounding 19 6.06 1.06834E−05 5 actin binding 17 4.07 7.06132E−07
3 response to external stimulus 23 8.48 1.35735E−05 3 enzyme inhibitor activity 16 4.12 3.93645E−06
3 localization 68 43.15 4.023E−05 5 guanyl nucleotide binding 13 5.85 .006071454
4 response to unfolded protein 7 0.98 4.94329E−05 4 carrier activity 12 4.98 .004386769
4 response to protein stimulus 7 0.98 4.94329E−05 4 protease inhibitor activity 11 2.39 2.79983E−05
4 establishment of localization 67 42.74 5.55917E−05 5 endopeptidase inhibitor
activity 11 2.37 2.6147E−05
4 platelet activation 4 0.31 .000205689 3 structural constituent of
cytoskeleton 9 1.59 2.93143E−05
4 tissue development 12 3.69 .000335856 3 antigen binding 8 1.01 6.94074E−06
3 response to stress 28 14.03 .000359514 3 unfolded protein binding 7 1.87 .002692475
3 response to chemical
stimulus 17 6.71 .000415494 4 protein binding bridging 5 1.26 .008431955
3 cell adhesion 23 11.26 .000908494 3 vitamin binding 5 1.29 .009440404
4 muscle contraction 9 2.55 .001043693 4 translation elongation
factor activity 4 0.33 .000285878
3 cellular localization 22 10.83 .001255793 4 intramolecular
oxidoreductase activity 4 0.72 .005532653
3 cell diﬀerentiation 21 10.27 .001492504 3 structural constituent of
muscle 4 0.59 .002785384
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Figure 4: Bioinformatic analysis of the fractionated platelet releasate. (a) Gene ontology (GO) terms found to be signiﬁcantly enriched in
the experimental dataset of platelet releasate proteins (“Observed”) in comparison to a reference dataset of human proteins (“Expected”)
along with the GO level associated with each individual ontological term. (b) The range of molecular weights (left panel) and isoelectric
points (right panel) of proteins identiﬁed in this study.
protein fractions separated by IEC to a biological assay
of monocyte cell migration. The denaturing conditions of
gel-based protein separation largely preclude subsequent
functional analysis of the proteins. However, a recently
developed nondenaturing 2DE method used for the analysis
of the Shewanella oneidensis microbial proteome may have
applications for functional analysis of separated protein
mixtures in the future [32]. The enzymatic activity of
malatedehydrogenasesfromthisbacteriumwasretainedand
identiﬁed within the polyacrylamide gel following 2DE [32].
In total, 315 unique proteins were identiﬁed in this anal-
ysis of platelet releasate. Proteins which we have previously
identiﬁed such as ﬁbrinogen, albumin, thrombospondin,
haemoglobin, platelet factor 4, platelet basic protein, and8 Journal of Biomedicine and Biotechnology
Table 1: Most abundant 50 proteins determined in the study (fractions 1–49).
Accession number Description 1-7 8-14 15-21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46-49
IPI00745872.2 Isoform 1 of serum albumin precursor -- -- 11 28 1807 32 7 45 5 -- 12 ---------- 37 --- -
IPI00022434.4 Uncharacterized protein alb -- -28 39 821 5 73 2 7 8 2 1 2 0 2 2 4 2 2 9 4 1 1 1451135 3 8 13 -- -
IPI00008669.4 Uncharacterized protein ensp00000257935 -- -43 75 - 15 32 -- 26 69 7 57 ----------- - - -
IPI00796364.1 51 kda protein -- -22 52 - 14 23 -- 10 55 - 62 - 5 --------- - - -
IPI00021439.1 Actin; cytoplasmic 1 -- -33 14 - 51 21 20 22 39 - 13 12 3 ---------- - - -
IPI00745872.2 Serum albumin (cell growth inhibiting protein 42) - - - --- - - - ---------------- 134 58 -
IPI00298497.3 Fibrinogen beta chain precursor -- -- 59 30 13 30 18 2 ---------------27 --
IPI00022434.3 Alb protein 14 11 8 --- - - - ----------------46 60 29
IPI00021891.5 Isoform gamma-b of fibrinogen gamma chain precursor -- -- 66 28 17 26 14 ---------------- - - -
IPI00027547.2 Dermcidin precursor - 1 2 2 7 24 6 2 15 6 10 7 31 10 5 ------ 11 -- - 2 -
IPI00884222.1 Similar to keratin, type 1 cytoskeletal 10 - - - --- - -62 ---- 54 ----------- - - -
IPI00021841.1 Apolipoprotein a-i precursor - - - ---15 - 3 ---14- 2 ---------67 9 -
IPI00013933.2 Isoform dpi of desmoplakin -- -27 - 4 --5 - 26 3 2 8 ----------- - - -
IPI00784154.1 60 kda heat shock protein; mitochondrial precursor -- -60 2 - - - - ----24 1 4--------- - - -
IPI00296099.6 Thrombospondin-1 precursor - - - --- -37 32 10 --------------- - - -
IPI00016801.1 Glutamate dehydrogenase 1; mitochondrial precursor -- -28 28 - - - - ---- 16 3 ---------- - - -
IPI00021885.1 Isoform 1 of fibrinogen alpha chain precursor -- -- 19 12 17 19 5 ------1 --------- - - -
IPI00478003.1 Alpha-2-macroglobulin precursor -- -- 3 - 9 - 13 ----------------46 --
IPI00022445.1 Platelet basic protein precursor -- -- 25 31 11 2228 3432--------- - - -
IPI00419424.3 Igkv1-5 protein -- -- 12 7 - 2 ---3 ----------2 - 33 1 -
IPI00021885.1 Splice isoform 1 of fibrinogen alpha chain precursor - - - --- - - - ----------------42 9 -
IPI00217960.1 Isoform 2 of camp-dependent PK; alpha-catalytic subunit -- -17 12 - - - - ----9 ----------- - - -
IPI00019502.3 Myosin-9 - - - ---19 --11 8 -------------- - - -
IPI00164623.4 Complement c3 precursor - - - --- - - - ----------------37 --
IPI00022446.1 Platelet factor 4 precursor - - - --- - - - --------------16 72 2 -
IPI00022463.1 Serotransferrin precursor - - - --- - - - ---3 ----------3 - 30 --
IPI00453473.6 Histone h4 -- -24- 433--566----------- - - -
IPI00021536.1 Calmodulin-like protein 5 -- -- - 51 2--- - - 7 8 ----------- - - -
IPI00298994.6 Uncharacterized protein tln1 - - - --- -31 - ---------------- - - -
IPI00219221.3 Galectin-7 -- -8 32 6 --- - - 8 1 ----------- - - -
IPI00384938.1 Hypothetical protein dkfzp686n02209 - - - --- - - - ----------------26 --
IPI00783987.2 Complement c3 precursor (fragment) -- -4 -- 6 - 15 ---------------- - - -
- IPI00015614.3 Isoform a of trypsin-3 precursor - - - --- - - - ------2 - 357- 4 - 3 ---
IPI00431645.1 Hp protein -- -- 591 0- - ---------------- - - -
IPI00302592.2 Filamin a; alpha isoform 1 - - - --- -23 - ---------------- - - -
IPI00004358.4 Glycogen phosphorylase; brain form -- -19 -- - - - ----22---------- - - -
IPI00022204.2 Serpin b3 -- -- - 59--- - - 9 ------------ - - -
IPI00027462.1 Protein s100-a9 -- -- - 41 6--- - - 2 ------------ - - -
IPI00021891.5 Splice isoform gamma-b of fibrinogen gamma chain precursor - - - --- - - - ----------------21 --
IPI00154742.6 Iglc1 protein - - - --- - - - ----------------20 --
IPI00291175.7 Isoform 1 of vinculin - - - --- -20 - ---------------- - - -
IPI00553177.1 Alpha-1-antitrypsin precursor - - - --- - - - ----------------18 --
IPI00025753.1 Desmoglein-1 precursor -- -5 - 3 ---- - 262----------- - - -
IPI00026314.1 Isoform 1 of gelsolin precursor - - - --- - 31 4---------------- - - -
IPI00017601.1 Ceruloplasmin precursor -- -1 -- - -15 ---------------- - - -
IPI00003935.6 Histone h2b type 2-e -- -52---1 ---6 ------------ - - -
IPI00383164.1 Snc66 protein - - - --- - - - ----------------14 --
IPI00008603.1 Actin; aortic smooth muscle - 32 --- - - - 2 --4 - 2 ---------- - - -
IPI00010951.2 Epiplakin -- -5 -- 2 --- - - 6 ------------ - - -
IPI00654755.3 Hemoglobin subunit beta -- -- 14 3 5 - ---------------- - - -
89kDa
43kDa
Rest TRAP Rest TRAP
Donor 1 Donor 2
(a)
131kDa
89kDa
Rest TRAP Rest TRAP
Donor 1 Donor 2
(b)
Figure 5: Western blot validation of novel platelet proteins. 30μL of resting and TRAP-stimulated platelet releasate were separated on a
4%–20% gradient SDS-PAGE gel and probed for PEDF and involucrin. (a) PEDF was detected as a band at approximately 50kDa, with
additional heavier bands that may represent glycosylated forms of the protein. (b) Involucrin was detected at the expected molecular
weight as a band resolving at approximately 120kDa. The locations of molecular weight markers are also indicated. These proteins were
identiﬁed in TRAP-stimulated platelet releasates from 4 individual donors. Images displayed are representative of the 4 individual donors. R
= Resting/unstimulated platelet releasate T = TRAP-stimulated platelet releasate.Journal of Biomedicine and Biotechnology 9
Table 2: Proteins identiﬁed in Fraction 27.
IPI no. Protein name Spectral
count
Other fractions
where protein was
found
Description
Previously
found in
platelets
IPI00745872.2 Isoform 1 of serum
albumin precursor 274 23–26, 28, 31, 42 Serum albumin Yes
IPI00022434.4 Uncharacterized protein
alb 78 22–26, 28–43, Albumin protein Yes
IPI00021439.1 Actin, cytoplasmic 1 20 22-23, 25-26,
28–29, 31–33
Highly conserved
cytoskeletal protein involved
in cell motility
Yes
IPI00298497.3 Fibrinogen beta chain,
precursor 18 23–26, 28, 44
Yields monomers that
polymerize ﬁbrin and act as
a cofactor in platelet
aggregation
Yes
IPI00021891.5
Isoform gamma-b of
ﬁbrinogen gamma chain
precursor
14 23–26
Yields monomers that
polymerize ﬁbrin and act as
a cofactor in platelet
aggregation
Yes
IPI00027547.2 Dermcidin precursor 15 8–26, 28–32, 34,
41, 45
Antimicrobial activity and
survival promoting peptide
for neurons
IPI00884222.1 Similar to keratin, type 1
cytoskeletal 10 62 32 Heterotetramer of two type I
and two type II keratins
IPI00021841.1 Apolipoprotein a-i
precursor 3 25, 31-32, 34,
44–45
Participates in reverse
transport of cholesterol from
tissues to the liver
IPI00013933.2 Isoform dpi of
desmoplakin 5 22, 24, 29–32 High molecular weight
protein of desmosomes
IPI00296099.6 Thrombospondin-1
precursor 32 26, 28
Adhesive glycoprotein that
mediates cell-to-cell and
cell-to-matrix interactions
Yes
IPI00021885.1 Isoform 1 of ﬁbrinogen
alpha chain precursor 5 23–26, 34
Cofactor in platelet
aggregation and yield
monomers that polymerize
into ﬁbrin
Yes
IPI00478003.1 Alpha-2-macroglobulin
precursor 13 23, 25, 44 Protease inhibitor
IPI00022445.1 Platelet basic protein
precursor 12 23–26, 28–34
Precursor for a number of
peptides with antimicrobial
(TC-1 and TC-2),
chemoattractant, and
stimulation of DNA
synthesis activity
Yes
IPI00419424.3 Igkv1-5 protein 2 23–25, 31, 42,
44–45 Immunoglobulin
IPI00453473.6 Histone h4 3 22-23, 25-26,
30–32, 34, 36
Core component of
nucleosomes playing a
central role in DNA repair,
replication, and
transcription
IPI00783987.2 Complement c3 precursor
(fragment) 15 22, 25
Involved in activation of the
complement system and
local inﬂammation
IPI00026314.1 Isoform 1 of gelsolin
precursor 14 26 Calcium-regulated,
actin-modulating protein Yes
IPI00022434.4 Uncharacterized protein
alb. 78 22–26, 28–43 Uncharacterized albumin
protein Yes10 Journal of Biomedicine and Biotechnology
Table 2: Continued.
IPI no. Protein name Spectral
count
Other fractions
where protein was
found
Description
Previously
found in
platelets
IPI00017601.1 Ceruloplasmin precursor 15 22
Glycoprotein involved in
iron transport across cell
membrane
IPI00382606.1 Factor vii active site mutant
immunoconjugate 44 5 Initiates extrinsic pathway of
blood coagulation
IPI00154742.6 Igl@ protein 2 24-25, 31 Immunoglobulin
IPI00550991.3 Alpha-1-antichymotrypsin
precursor 64 4 Inhibits neutrophil cathepsin
G and mast cell chymase
IPI00025252.1 Protein disulﬁde-isomerase
a3 precursor 42 6 Catalyses the rearrangement
of S-S bonds in proteins Yes
IPI00022431.1 Alpha-2-hs-glycoprotein
precursor 34 4
Secreted protein, part of the
fetuin family, may be
involved in diﬀerentiation
Yes
IPI00032292.1 Metalloproteinase inhibitor
1p r e c u r s o r 3
Complexes with
metalloproteinases and
irreversibly inactivates them
Yes
IPI00555812.4 Vitamin d-binding protein
precursor 1 23, 44
Multifunctional protein
found in many body ﬂuids
and on the surface of various
cell types
Yes
IPI00179709.4 Isoform 1 of tubulin
alpha-3c/d chain 2 Major constituent of
microtubules
IPI00006114.4 Proliferation-inducing
protein 35/PEDF 2
Induces neuronal
diﬀerentiation and inhibits
angiogenesis
Yes
IPI00739464.1 Similar to cytoplasmic
beta-actin 13 1
Highly conserved
cytoskeletal protein involved
in cell motility
Yes
IPI00414860.6 60s ribosomal protein l37a 1
Ribosomal protein
containing a zinc ﬁnger
domain, expressed in many
cell types
Yes
IPI00020996.3
Insulin-like growth
factor-binding protein
complex acid labile chain
precursor
1
Secreted protein involved in
protein complexes with
insulin-like growth factor
family
IPI00418471.6 Vimentin 1
Class III intermediate
ﬁlament protein found in
many nonepithelial cells
Yes
actin binding proteins were well represented [1]. While it
cannot be discounted that some of these proteins may be
residual serum proteins or proteins derived from cellular
debris, the identiﬁcations detailed in this study are in
agreement with previous publications from our laboratory
and further aﬁeld (see [1, 2, 4, 27, 33–36]).
We also report the identiﬁcation of proteins which have
previously been implicated in neuronal exocytosis such as
calmodulin-like protein 3 in Fraction 25 [37] and pleckstrin
and sec7 domain protein in Fractions 22 and 26, respectively,
[38]. Pigment epithelium-derived factor (PEDF) was also
identiﬁed in the platelet releasate by mass spectrometric
methods and its presence was validated by western blot.
PEDF is a potent inhibitor of angiogenesis in the eye [39]
and has also been detected in plasma and serum [40, 41].
Interestingly, a recent study suggests that pro- and anti-
angiogenic proteins within the platelet may be separated into
distinct subsets of alpha granules which are diﬀerentially
released depending on the agonist [42]. We also conﬁrmed
the presence of involucrin, a protein found as a component
of scaﬀolding in the cell envelope of stratiﬁed epithelium, in
theplateletreleasatebywesternblotting.ThisproteinhasnotJournal of Biomedicine and Biotechnology 11
been previously identiﬁed in nonepithelial cell types to the
best of our knowledge.
Previous studies in our laboratory established that the
platelet releasate had a much greater pro-migratory eﬀect on
THP-1 monocytes than on human arterial smooth muscle
cellsorhumanretinalendothelialcells(datanotshown).The
use of ion-exchange fractionation enabled us to locate the
pro-migratory activity of the platelet releasate to just one of
49 Fractions. Candidate proteins which may be responsible
for the monocyte pro-migratory activity of Fraction 27
include tissue inhibitor of metalloproteinase 1 (TIMP-1) and
proliferation-inducing protein 35 (PEDF). Future studies
willfocusonidentifyingthepotentialpro-migratoryprotein,
orproteins,inFraction27byusingneutralizingantibodiesin
our cell-based assay, against some of the identiﬁed proteins.
A decrease in the biological activity of the candidate protein
due to the presence of a neutralizing antibody would further
support its pro-migratory eﬀect in our cell assay.
However it is also possible, despite the extensive protein
separation methods used, that the protein responsible for the
migratory activity is a small protein of low abundance which
may never be captured by mass spectrometry. Antibody
arrays of growth factors and cytokines may also assist in
the identiﬁcation of the pro-migratory protein secreted by
platelets. Using this technology we have previously shown
that PDGF, angiogenin, RANTES, and many other cytokines
and growth factors are secreted by platelets following
t h r o m b i na c t i v a t i o n[ 27]. These proteins were not identiﬁed
in any fraction in the current mass spectrometric study of
the platelet releasate. Investigation of the contribution of
some likely pro-migratory cytokine candidates within the
platelet releasate has ruled out certain proteins in terms of
monocyte migration. Anti-RANTES neutralizing antibodies
had no eﬀect on platelet releasate-induced THP-1 monocyte
migration (data not shown). It seems unlikely that MCP-1
is the chemokine responsible for platelet releasate-induced
THP-1 migration because 100ng/mL MCP-1 induced a
much lower level of THP-1 migration than TRAP-stimulated
platelet releasate.
Both collagen I and collagen IV were identiﬁed in Frac-
tion 27 but not in any other fraction, and previous studies in
our laboratory have shown a pro-migratory eﬀectof collagen
I on arterial smooth muscle cells, so we also investigated
the eﬀect of these extracellular matrix proteins on THP-1
migration. However, no evidence of a pro-migratory eﬀect
was observed (data not shown). In addition, the possibility
that a group of proteins rather than an individual protein in
Fraction 27 contributed to the pro-migratory eﬀect can not
be discounted without further investigation.
In summary, the approach outlined in the current
study facilitated the penetration of the platelet releasate
proteome to a suﬃcient degree to increase the number
of low-abundance identiﬁcations. This in turn highlighted
candidate proteins responsible for platelet releasate induced
monocyte cell migration which merit further targeted func-
tional analysis. The method described here could be equally
applied to other secretory systems and biological situations
involving the functional analysis of secreted proteins from
one cell type on another cell function.
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